Interim report January - March 2019: High profitability and new business unit

2019-04-23 08:30

First quarter:
· Sales amounted to SEK 312 (264) million, corresponding to an increase of 18 percent in SEK. Sales increased by 12 percent in local currency whereof 4 percent comprised organic growth.
· Operating income before depreciation and amortisation (EBITDA) amounted to SEK 126 (106) million, corresponding to a margin of 40 (40) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 14 million.
· Net income amounted to SEK 86 (72) million, which gave earnings per share of SEK 0.79 (0.66).
· Market approval for EmbryoScope+ in China.

After the end of the period:
· Acquisition and collaboration agreement regarding technology for embryo assessment using artificial intelligence. The initial purchase price in connection with the transfer amounted to USD 6 million.

April 23, 2019
Gothenburg
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Report

Interim report January - March 2019

Presentations

Presentation telephone conference

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on April 23, 2019.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.